Bavarian Nordic A/S, of Copenhagen, said it started a phase I study of its MVA-BN RSV vaccine candidate against respiratory syncytial virus (RSV). The trial, being conducted in the U.S., will evaluate the safety, tolerability and immunogenicity of a recombinant MVA-BN-based RSV vaccine in 63 healthy adults, ages 18 to 65.